McKesson Corporation Overview and Analysis

McKesson Corporation is a leading healthcare services company that has been in operation for over 185 years. Founded in 1833, McKesson has a rich history of providing pharmaceutical and medical-surgical supply chain management services.

McKesson's early success was driven by its innovative approach to distributing medications and medical supplies. The company's first warehouse was established in San Francisco in 1852.

Today, McKesson is one of the largest healthcare companies in the world, with operations in more than 20 countries. The company's global reach allows it to provide a wide range of services to healthcare providers, manufacturers, and payers.

McKesson Corporation has a significant impact on the healthcare industry. The company's PBM services, such as its pharmacy benefit management operations, affect millions of Americans every year.

McKesson's PBM services are used by many major health insurance companies, including UnitedHealth Group and Aetna. This means that McKesson plays a crucial role in determining the cost of prescription medications for a large portion of the US population.

For more insights, see: Magellan Health Pbm

McKesson's distribution network is also a key factor in its industry impact. The company's distribution centers and warehouses cover over 12 million square feet of space, allowing it to efficiently deliver pharmaceuticals and medical supplies to hospitals, pharmacies, and other healthcare providers.

McKesson's acquisition of Celesio in 2015 expanded its international presence, with operations in 13 countries. This move has allowed McKesson to tap into new markets and increase its global reach.

McKesson Corporation has consistently demonstrated strong financial performance, with revenue reaching $276.711 billion in 2023.

The company's net income has also been steadily increasing, with a profit of $3.56 billion in 2023. This growth is a testament to McKesson's ability to adapt and thrive in a rapidly changing industry.

McKesson's financial stability is further reflected in its total assets, which reached $62.320 billion in 2023. The company's strong financial standing has allowed it to maintain a large workforce, with 51,000 employees as of 2023.

McKesson's financial performance has been steadily increasing over the years, with revenue growing from $79.1 billion in 2005 to $276.7 billion in 2023.

The company's net income has also seen significant growth, with a net income of $3.56 billion reported in 2023. This growth in revenue and net income has contributed to McKesson's strong financial standing.

McKesson's total assets have also increased over the years, with a total of $62.3 billion in assets reported in 2023. The company's price per share has also seen significant growth, with a price of $405.02 per share reported in 2023.

The company has consistently ranked among the top Fortune 500 companies, reflecting its strong financial standing and industry influence. McKesson's financial performance has been marked by steady growth, particularly in its pharmaceutical distribution segment.

Here's a breakdown of McKesson's revenue and net income over the years:

McKesson's profitability has also been a key area of focus, with a profit margin of 0.84% reported in the company's profitability and income statement. The company's return on assets (ROA) has also been impressive, with a ROA of 4.01% reported in 2023.

A unique perspective: What Does Ibnr Stand for

Understanding a company's seasonality profile is crucial for investors and analysts.

McKesson Corporation's seasonality profile shows a clear pattern of price fluctuations over time.

Each bar in the profile represents a calendar month, with percentages indicating how frequently each month closes higher than the one before it.

The vertical line in the profile indicates the current month, providing a snapshot of the company's current performance.

Some months, such as January, tend to close lower than the previous month, while others, like March, tend to close higher.

This pattern can be useful for investors looking to time their purchases or sales accordingly.

McKesson Corporation's seasonality profile is a valuable tool for understanding the company's financial performance over time.

See what others are reading: Brokers with No Pattern Day Trader Rule

McKesson Corporation operates across multiple core business segments that support healthcare organizations at every level of care delivery. These segments have been shaped by the company's divestment of its legacy health IT division in 2023.

The largest segment is Pharmaceutical Distribution, which distributes drugs and health products. McKesson's Pharmaceutical Distribution segment is the largest of its kind.

McKesson's core business also includes Medical-Surgical Supplies, which provides medical supplies and equipment to healthcare facilities. This segment offers a wide range of products and services to support healthcare providers.

Here are McKesson's core business segments:

McKesson's business operations are centered around its core business segments, which include pharmaceutical distribution, medical-surgical supplies, healthcare technology, and community oncology services.

The company's pharmaceutical distribution segment is its largest, distributing drugs and health products to a wide range of customers, including retail pharmacies, hospital systems, and long-term care facilities.

McKesson's medical-surgical supplies segment provides medical supplies and equipment to healthcare facilities, including physician offices, surgery centers, and home care agencies.

The company's healthcare technology segment offers software and analytics for healthcare systems, helping them to improve efficiency and effectiveness in healthcare delivery.

McKesson's community oncology services segment supports cancer care delivery in communities, providing practice management, technology, and clinical support to community-based oncology and other specialty practices.

A fresh viewpoint: Storage Facilities in Usa

Here are McKesson's core business segments in detail:

NDCHealth (Relay Health) was a company that underwent significant changes in the early 2000s.

NDCHealth became NDC-Health Corp in 2001 following a spin-off. It was renamed again to RelayHealth in 2007.

The company was acquired by McKesson in 2007 through the purchase of Per-Se Technologies.

A unique perspective: Chinese Stock Bubble of 2007

McKesson is a leader in healthcare technology, with a presence in the US market that's hard to ignore. They have a customer base that includes 50% of all health systems and 20% of all physician practices.

Their software development division, McKesson Provider Technologies, has made significant acquisitions, including Medcon, Ltd. in 2005, which added web-based cardiac image and information management solutions to their portfolio.

McKesson is a Fortune 500 company and one of the top 100 contractors of the US federal government. This level of influence gives them a unique perspective on the healthcare industry.

In the area of prescription technology, McKesson supports pharmaceutical manufacturers and payers in connecting patients with medication access, affordability, and adherence programs.

McKesson's technology and innovation efforts have led to the development of automated pharmacy distribution systems, cold chain logistics for vaccines and biologics, and digital patient access programs.

Some of McKesson's key innovations include AI-based medication tracking and radio frequency ID inventory tracking. These technologies have become critical in modern healthcare logistics.

Here are some of the key pieces of McKesson's technology puzzle:

McKesson Corporation has made corporate responsibility and ESG efforts a priority, focusing on reducing carbon emissions, improving drug disposal and environmental safety, promoting diversity, equity, and inclusion, and expanding access to essential medications in underserved communities.

The company has set specific goals in these areas, demonstrating its commitment to sustainability. McKesson is also aware of the environmental impact of the pharmaceutical industry, which is a significant concern.

Suggestion: Shanxi Lu'an Environmental Energy

McKesson's ESG efforts are not without challenges, as organizations across industries encounter various business risks associated with ESG issues. However, by prioritizing sustainability, McKesson is taking steps to mitigate these risks and create a positive impact.

Here are some of McKesson's corporate sustainability goals at a glance:

The opioid epidemic is a stark reminder of the devastating consequences of corporate negligence. In 2008, McKesson paid $13 million in fines for failing to report large orders of hydrocodone.

McKesson's failure to track and stop suspicious opioid sales led to a $150 million civil penalty in 2017. This penalty was a result of the company's alleged violations of the Controlled Substances Act.

The company's actions had far-reaching consequences, with the Attorney General of Oklahoma suing McKesson in 2020, alleging that its actions helped fuel Oklahoma's opioid crisis. McKesson was accused of providing enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets.

In 2022, McKesson, along with other companies, agreed to pay $26 billion to settle with most of the states suing them. This settlement was a fraction of the potential $95 billion in penalties the companies could have faced if they had gone to court.

Check this out: Oklahoma State Banking Department

ESG Responsibility is a top priority for many companies, including McKesson, which has implemented corporate sustainability goals focused on reducing carbon emissions, improving drug disposal and environmental safety, promoting diversity, equity, and inclusion, and expanding access to essential medications in underserved communities.

These goals aim to minimize the environmental impact of the pharmaceutical industry, which is a significant contributor to greenhouse gas emissions. The industry's carbon footprint is a major concern, and companies like McKesson are taking steps to reduce their emissions.

McKesson's efforts are part of a broader trend in the healthcare industry, where companies are recognizing the importance of ESG responsibility. By prioritizing sustainability and social responsibility, these companies can mitigate risks and create long-term value.

Here are some key ESG risks and challenges in the healthcare industry:

These risks can have significant consequences for companies and the environment. By understanding these risks and taking proactive steps to mitigate them, companies can create a more sustainable and responsible future.

For another approach, see: What Risks Does Economic Growth Require

McKesson Corporation operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical (until spun-off).

McKesson is one of three leading pharmaceutical wholesalers in the US, accounting for over 90% of the US pharmaceutical wholesale industry along with Cencora and Cardinal Health.

The company engages in pharmaceutical wholesale and distribution in Canada and supplies medical-surgical products and equipment to healthcare facilities.

Here are some key facts about McKesson's operations:

McKesson Corp is one of the leading pharmaceutical wholesalers in the US, accounting for over 90% of the US pharmaceutical wholesale industry along with Cencora and Cardinal Health.

McKesson operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical.

The company is headquartered in Irving, Texas, and engages in pharmaceutical wholesale and distribution in Canada, in addition to its US operations.

McKesson supplies medical-surgical products and equipment to healthcare facilities and provides technology solutions for pharmacies.

Here are the company's main business segments:

Comparing companies can be a daunting task, but let's break it down. To do this, we can analyze similar companies using key performance metrics.

McKesson Corp is one of the three leading pharmaceutical wholesalers in the US, accounting for over 90% of the US pharmaceutical wholesale industry, along with Cencora and Cardinal Health.

When looking at similar companies, it's helpful to consider the market share of each company. Here's a table comparing the market share of McKesson with some of its competitors:

By analyzing the market share of each company, we can get a better sense of how they compare to one another.

McKesson Corporation has been at the forefront of the COVID-19 pandemic response. In August 2020, the company was selected as the U.S. government's centralized distributor for COVID-19 vaccine doses and ancillary supply kits under Operation Warp Speed.

McKesson played a key role in distributing the Moderna and Johnson & Johnson vaccines across the U.S., in addition to distributing ancillary supply kits for these vaccines.

Recommended read: Astra Zeneca Covid

The COVID-19 pandemic has been a challenging time for many of us, and the US government took swift action to combat it. In August 2020, the CDC and HHS selected McKesson as the U.S. government's centralized distributor for COVID-19 vaccine doses and ancillary supply kits under Operation Warp Speed.

McKesson played a key role in distributing the Moderna and Johnson & Johnson vaccines across the US. They also distributed ancillary supply kits for these vaccines, as well as for the Pfizer–BioNTech vaccine.

McKesson supported the US government in efforts to send doses and kits abroad, helping to combat the pandemic on a global scale.

You might like: Bcbs Ancillary

McKesson is poised to thrive in the future, driven by advancements in healthcare technology and a growing demand for efficient supply chain solutions.

The company is well-positioned to capitalize on emerging trends in telemedicine, personalized healthcare, and digital health records. This is a promising area for growth, as more healthcare providers adopt these innovative approaches.

McKesson's commitment to sustainable and ethical business practices is also a significant advantage. By prioritizing corporate responsibility and equitable healthcare access, the company is aligning itself with the values of a changing world.

Its initiatives to address healthcare disparities are a key part of this effort, demonstrating a genuine commitment to making a positive impact.

Take a look at this: Kingsbury Commitment

McKesson Corporation has a rich history that spans over 180 years. It was founded in 1833 by John McKesson and Charles Olcott in New York City.

The company initially started as a pharmaceutical import and wholesale business. This marked the beginning of a long journey that would see McKesson evolve significantly over the years.

In 1853, the company was renamed McKesson & Robbins after an employee, Daniel Robbins, became a partner in the firm. By then, the company was distributing pharmaceutical products by covered wagon to 17 states and territories across America.

Here's a brief timeline of McKesson's major milestones:

Today, McKesson operates in multiple locations across the globe, emphasizing its international presence and diversified business operations.